Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, by Drug Type (Stimulants (Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, and Lisdexamfetamine Dimesylate) and Non-stimulants (Atomoxetine, Bupropion, Guanfacine, and Clonidine), by Age Group (Pediatric and Adolescent, and Adult), by Distribution Channel (Specialty Clinics, Hospital Pharmacies, Retail Pharmacies, and E-commerce), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 18,169.0  million in 2020 and is expected to exhibit a CAGR of 7.1 % during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Key companies are focusing on rising approval of new products from the regulatory authority, in order to provide better options for treatment of ADHD in pediatric and adolescent patients, which is expected to bolster market growth over the forecast period. For instance, in August 2018, Ironshore Pharmaceuticals & Development, Inc., a subsidiary of Highland Therapeutics Inc., received the U.S. Food and Drug Administration (FDA) approval for its New Drug Application (NDA) for JORNAY PM (methylphenidate) for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 years and older.

Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market – Impact of Coronavirus (COVID-19)

  • The COVID-19 pandemic has drastically impacted each and every market across the world. Therefore, government of various countries are taking initiatives to combat attention-deficit hyperactivity disorder (ADHD) amid Covid-19.
  • In order to manage attention deficit hyperactivity disorder (ADHD) during the COVID-19 pandemic, organizations such as National Resource Center on ADHD (NRC), Children and Adults with Attention-Deficit/ Hyperactivity Disorder (CHADD), and others provide education and support, and spread awareness about attention deficit hyperactivity disorder among the patients suffering from ADHD. Such organizations are funded by government organizations including the Centers for Disease Control and Prevention (CDC). For instance, on July 1, 2020, the Center for Disease Control and Prevention (CDC) highlighted the negative effects of social distancing. They reported that social distancing increased mental stress among the people and it is more evident in ADHD patients, due to which the behavioral problems in some of the ADHD patients have become worse.

Browse 35 Market Data Tables and 38 Figures spread through 181 Pages and in-depth TOC on “Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, by Drug Type (Stimulants (Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, and Lisdexamfetamine Dimesylate) and Non-stimulants (Atomoxetine, Bupropion, Guanfacine, and Clonidine), by Age Group (Pediatric and Adolescent, and Adult), by Distribution Channel (Specialty Clinics, Hospital Pharmacies, Retail Pharmacies, and E-commerce), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)”

To know the latest trends and insights prevalent in the global attention deficit hyperactivity disorder (ADHD) therapeutics market, click the link below:

https://www.coherentmarketinsights.com/market-insight/attention-deficit-hyperactivity-disorder-treatment-market-830

The market is expected to witness significant growth during the forecast period, owing to key players focusing on launch of new ADHD services and formation of new hubs for the diagnosis, assessment, and treatment of ADHD. For instance, in September 2020, Nottinghamshire Healthcare announced the launch of attention deficit hyperactivity disorder (ADHD) service, wherein adults with ADHD in Nottinghamshire can receive the support for diagnostic assessment and the right treatment.

Key Takeaways of the Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market:

  • The global attention deficit hyperactivity disorder (ADHD) therapeutics market is expected to exhibit a CAGR of 7.1% during the forecast period, owing to key companies focusing on product launches and approval for the treatment of attention deficit hyperactivity disorder (ADHD)
  • Among drug type, stimulants segment is expected to hold major market share in the global attention deficit hyperactivity disorder (ADHD) therapeutics market during the forecast period, owing to an increasing number of launch of new products for the treatment of patients with ADHD by key companies
  • Among age group, adults segment is expected to hold major market share in the global attention deficit hyperactivity disorder (ADHD) therapeutics market during the forecast period, owing to increasing prevalence of attention deficit hyperactivity disorder (ADHD) in adult population globally
  • Among distribution channel, retail pharmacies segment is expected to hold major market share in the global attention deficit hyperactivity disorder (ADHD) therapeutics market during the forecast period, owing to increasing number of retail pharmacies & chain stores, easy access of products, and strategic tie-ups between major companies & retail pharmacies
  • Key players operating in the global attention deficit hyperactivity disorder (ADHD) therapeutics market include Amneal Pharmaceuticals, Inc., Eli Lilly And Company, Janssen Pharmaceuticals, Inc., Noven Pharmaceuticals, Inc., RespireRx Pharmaceuticals Inc., Otsuka Pharmaceutical Co., Ltd, Neos Therapeutics, Inc., American Brivision (Holding) Corporation, Novartis International AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc., and Purdue Pharma L.P.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner